Aclaris Therapeutics is a biopharmaceutical company that develops drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes Zunsemetinib, which is for the indication of rheumatoid arthritis (moderate to severe), psoriatic arthritis (moderate to severe), and hidradenitis suppurativa (moderate to severe); ATI-1777, which is for the indication of atopic dermatitis (moderate to severe); ATI-2138, which is for the indication of T cell-mediated autoimmune diseases; Gut-Biased Program, which is for the indication of inflammatory bowel disease; and ATI-2231, which is for the indication of metastatic breast cancer and pancreatic cancer. We show 37 historical shares outstanding datapoints in our coverage of ACRS's shares outstanding history.
Understanding the changing numbers of ACRS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRS by allowing them to research ACRS shares outstanding history
as well as any other stock in our coverage universe. |
Free ACRS Email Alerts:
Video: Shares Outstanding Importance
